Use of pteridinone derivative serving as EGFR inhibitor

US11306095B2 · kind B2 · utility

Assignee

• East China University of Science and Technology · CN

Inventors

• Honglin Li · Shanghai, CN
• Yufang Xu · Shanghai, CN
• Zhenjiang ZHAO · Zhuhai, CN
• Wei Zhou · Scotch Plains, US
• Yuqiong Xu · Hangzhou City, CN
• Deheng Sun · Shanghai, CN
• Xia Wang · San Diego, US
• Zhuo Chen · Beijing, CN

Key dates

• Filing date: May 30, 2016
• Grant date: Apr 19, 2022
• Expiry date: May 30, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D475/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.